HIF 1 α - a promising target for the treatment of meningiomas.
HIF 1α
meningioma
promising
target
Journal
Medicine and pharmacy reports
ISSN: 2668-0572
Titre abrégé: Med Pharm Rep
Pays: Romania
ID NLM: 101742144
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
02
2021
revised:
03
05
2022
accepted:
29
12
2022
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Meningiomas are the most frequent tumors of the brain and spinal cord with a potency to recur in around one third of the cases and and invade surrounding tissue. Hypoxia driven factors like HIFs (Hypoxia inducible factors) are implicated in tumor cell growth and proliferation. This study aims at determining the association of HIF 1 α with different histopathological grades and types of meningiomas. This prospective study was conducted on 35 patients. The patients presented with headache (65.71%), seizures (22.86%) and neurological deficits (11.43%). They underwent surgical excision and surgical tissue samples of these patients were histopathologically processed and microscopically graded and typed. Immunohistochemistry was performed using anti-HIF 1α monoclonal antibody. The nuclear expression of HIF 1 α was graded as <10%: negative, 11-50%: mild to moderate positive, >50%: strong positive. Of the 35 cases so examined 20% were recurrent; 74.29% were WHO grade I with meningothelial type (22.86%), being the commonest; 57.14 % revealed mild to moderate positivity for HIF 1α, while strong positivity was noted in 28.57%. Significant association was found between WHO grade and HIF 1α (p=0.0015) and between histopathological types and HIF 1α (p=0.0433). Furthermore, HIF 1α was also significantly associated with the recurrent cases (p=0.0172). HIF 1α appears to be a marker and a promising target for effective therapeutics in meningiomas.
Sections du résumé
Background
UNASSIGNED
Meningiomas are the most frequent tumors of the brain and spinal cord with a potency to recur in around one third of the cases and and invade surrounding tissue. Hypoxia driven factors like HIFs (Hypoxia inducible factors) are implicated in tumor cell growth and proliferation.
Aim
UNASSIGNED
This study aims at determining the association of HIF 1 α with different histopathological grades and types of meningiomas.
Methods
UNASSIGNED
This prospective study was conducted on 35 patients. The patients presented with headache (65.71%), seizures (22.86%) and neurological deficits (11.43%). They underwent surgical excision and surgical tissue samples of these patients were histopathologically processed and microscopically graded and typed. Immunohistochemistry was performed using anti-HIF 1α monoclonal antibody. The nuclear expression of HIF 1 α was graded as <10%: negative, 11-50%: mild to moderate positive, >50%: strong positive.
Results
UNASSIGNED
Of the 35 cases so examined 20% were recurrent; 74.29% were WHO grade I with meningothelial type (22.86%), being the commonest; 57.14 % revealed mild to moderate positivity for HIF 1α, while strong positivity was noted in 28.57%. Significant association was found between WHO grade and HIF 1α (p=0.0015) and between histopathological types and HIF 1α (p=0.0433). Furthermore, HIF 1α was also significantly associated with the recurrent cases (p=0.0172).
Conclusion
UNASSIGNED
HIF 1α appears to be a marker and a promising target for effective therapeutics in meningiomas.
Identifiants
pubmed: 37197281
doi: 10.15386/mpr-2059
pii: cm-96-170
pmc: PMC10184527
doi:
Types de publication
Journal Article
Langues
eng
Pagination
170-174Références
Nature. 1999 May 20;399(6733):271-5
pubmed: 10353251
Biomed Res Int. 2015;2015:646853
pubmed: 25821815
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Cancer Res Treat. 2004 Dec;36(6):343-53
pubmed: 20368827
Yonsei Med J. 2017 May;58(3):489-496
pubmed: 28332352
Cell. 2012 Feb 3;148(3):399-408
pubmed: 22304911
Biomed Res Int. 2020 Aug 29;2020:1682352
pubmed: 32908869
Neurosurgery. 2012 Jul;71(1):146-56
pubmed: 22472549
EMBO J. 1998 Nov 16;17(22):6573-86
pubmed: 9822602
Cancer Res. 1999 Aug 15;59(16):3915-8
pubmed: 10463582
Cancer Res. 2003 Mar 1;63(5):1138-43
pubmed: 12615733
J Clin Neurosci. 2008 Sep;15(9):1036-42
pubmed: 18621534
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Clin Neuropathol. 2012 Sep-Oct;31(5):352-60
pubmed: 22541785
Front Biosci. 2003 Jan 01;8:d100-16
pubmed: 12456339
Science. 2001 Apr 20;292(5516):464-8
pubmed: 11292862
Vasc Health Risk Manag. 2006;2(3):213-9
pubmed: 17326328
Gene Ther. 2001 Apr;8(8):638-45
pubmed: 11320410
Oncogene. 2003 May 22;22(21):3213-20
pubmed: 12761491
Neuropathol Appl Neurobiol. 1998 Feb;24(1):3-8
pubmed: 9549723
Int J Neurosci. 2013 Sep;123(9):657-62
pubmed: 23550771
Hum Pathol. 1991 Feb;22(2):172-8
pubmed: 1848205
Cancer Sci. 2018 Mar;109(3):560-571
pubmed: 29285833